Gilead Sciences Inc.
Gilead Sciences Reports Third Quarter 2024 Financial Results
Summary
Gilead Sciences, Inc. announced its third quarter 2024 financial results, showing a 7% year-over-year increase in total revenue to $7.5 billion. Product sales, excluding Veklury, grew by 7% to $6.8 billion. Biktarvy sales increased by 13%, while oncology sales rose by 6%. Gilead also provided updated financial guidance for the full year 2024. The press release and reconciliation tables are furnished as Exhibit 99.1.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement